---
title: "CoreWeave stock pops 16% after outlook raise eases AI slowdown concerns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305140734.md"
description: "CoreWeave shares surged over 15% in premarket trading after reporting Q3 revenue of $3.7 billion, a 168% increase, and raising full-year guidance. The results alleviated investor concerns regarding the sustainability of AI investments and credit distress signals. CEO Michael Intrator called it a 'breakout quarter' supported by customer prepayments. Analysts view the strong financial performance as a potential bottom for the stock, citing reduced downside risk."
datetime: "2026-11-11T09:09:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305140734.md)
  - [en](https://longbridge.com/en/news/305140734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305140734.md)
generator: "portal-rs"
---

# CoreWeave stock pops 16% after outlook raise eases AI slowdown concerns

CoreWeave shares jumped in premarket trading Wednesday after the neocloud posted quarterly earnings that beat estimates and raised its guidance for the year.

Neoclouds such as CoreWeave, Nebius and IREN have come under scrutiny this month as investors assessed the sustainability of the AI trade. CoreWeave, in particular, sparked alarm when spreads on its CDS widened past 11%, generally viewed as a distress level, as investors have to pay up for protection against default.

Revenue jumped 168% to $3.7 billion in the third quarter, the company said in a Tuesday statement. 

The three months to Sept. 30 marked a "breakout quarter" for CoreWeave, CEO Michael Intrator said, adding that growth was supported by multiple sources of funding, including financing backed by customer contracts and around $9 billion in customer prepayments and deposits.

Shares were 15.4% higher as of 4:06 a.m. ET.

Stock chart icon

CoreWeave shares this year.

CoreWeave expects $1.275 billion to $1.375 billion in adjusted operating income on $13 billion to $13.3 billion in revenue. Analysts surveyed by Visible Alpha were looking for $1.07 billion in adjusted operating income, and analysts polled by LSEG had expected $12.86 billion in 2026 revenue.

The neocloud has done well to allay concerns about financing by moving away from unsecured bond financing, Zacks Chief Equity Strategist John Blank told CNBC's "Squawk Box Europe."

"It might be the bottom for CoreWeave," Blank said Wednesday. "But the shares are so beaten up, you have to believe at this point there's more value on the upside than the down."

***This is a breaking news story. Please refresh for updates.***

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

### Related Stocks

- [CRWV.US](https://longbridge.com/en/quote/CRWV.US.md)
- [CORD.US](https://longbridge.com/en/quote/CORD.US.md)
- [CRWG.US](https://longbridge.com/en/quote/CRWG.US.md)
- [CRWU.US](https://longbridge.com/en/quote/CRWU.US.md)
- [CRWX.US](https://longbridge.com/en/quote/CRWX.US.md)
- [CWVX.US](https://longbridge.com/en/quote/CWVX.US.md)
- [CWY.US](https://longbridge.com/en/quote/CWY.US.md)
- [IREN.US](https://longbridge.com/en/quote/IREN.US.md)
- [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md)

## Related News & Research

- [CoreWeave Surges 17% Premarket After Earnings, Beats Revenue Estimates and Raises Full-Year Guidance](https://longbridge.com/en/news/305156182.md)
- [CoreWeave says demand is outstripping capacity – CFO defends AI expansion: 'Today's environment very profitable' for differentiated technology](https://longbridge.com/en/news/305101338.md)
- [BUZZ-PREVIEW: CoreWeave's AI financing in focus ahead of results](https://longbridge.com/en/news/305044373.md)
- [CoreWeave Heads Into Earnings With AI Demand Red-Hot and Debt Under the Microscope](https://longbridge.com/en/news/305043404.md)
- [CoreWeave Signs Multi-Year Deal With Wayve for AI Driver Training](https://longbridge.com/en/news/304855875.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**